B.Riley initiates coverage on Axsome Therapeutics stock with Buy rating
PositiveFinancial Markets

B.Riley has started coverage on Axsome Therapeutics, giving it a 'Buy' rating, which is a strong endorsement for the company's stock. This is significant as it suggests confidence in Axsome's potential for growth and success in the market, attracting investor interest and possibly leading to an increase in stock value.
— Curated by the World Pulse Now AI Editorial System